Cashu
Wojcicki's Nonprofit Bests Regeneron in 23andMe Acquisition Amid Bankruptcy Struggles
2 days ago
Stocks
Health Care
regn
Regeneron Pharmaceuticals
REGN
+7.89 (+1.55%)
516.755
USD
At close at Jun 18, 15:36 UTC
Overview
Loading chart...
Key Stats
Market Cap
55.63B
Dividend Yield
0.00%
P/E Ratio
12.36
EPS
40.89
Revenue
14.20B
Avg. Volume
1.66M
About
What does REGN do?
Regeneron Pharmaceuticals, headquartered in Tarrytown, New York, focuses on developing medicines for serious diseases, employing 13,450 people. Its key products include EYLEA, Dupixent, and Libtayo, utilizing advanced technologies like VelociSuite.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.